Adma Biologics
Open
$8.27
Prev. Close
$8.27
High
$8.27
Low
$8.20
Market Snapshot
$1.96B
11.8
0.85
$426.45M
647
ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The company is headquartered in Ramsey, New Jersey and currently employs 647 full-time employees. The company went IPO on 2013-10-17. The firm manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
ADMA Biologics is currently facing class action lawsuits, which have significantly impacted investor confidence and led to a notable decline in its market value.
ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The company is headquartered in Ramsey, New Jersey and currently employs 647 full-time employees. The company went IPO on 2013-10-17. The firm manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
Recently from Cashu
ADMA Biologics Faces Class Action Lawsuits Over Financial Deception and Governance Concerns
ADMA Biologics is facing serious legal challenges as multiple law firms file class action lawsuits citing significant allegations against the company. The lawsuits accuse ADMA Biologics of engaging in…
ADMA Biologics Secures FDA Approval for Pediatric ASCENIV, Signaling Growth Potential
Adma Biologics (Ticker: ADMA) achieves a significant milestone with its recent approval from the FDA to expand the label for its product ASCENIV. This newly approved indication allows the use of ASCEN…
ADMA Biologics Faces Investigation Over Alleged Financial Misconduct and Stock Price Plummets
Concerns Arise Over ADMA Biologics' Financial Practices Amid Investigations ADMA Biologics, Inc. is currently facing scrutiny over its financial practices following a report by short seller Culper Res…
Financial Misconduct Allegations Create Concerns for ADMA Biologics' Integrity and Investor Confidence
Allegations of Financial Misconduct Cast a Shadow on ADMA Biologics A recent report from Culper Research has raised troubling allegations against ADMA Biologics, suggesting serious misrepresentations…